Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4,779.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 201,472 shares of the biotechnology company's stock after purchasing an additional 197,343 shares during the quarter. GAMMA Investing LLC owned 0.07% of Exelixis worth $7,438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. NorthCrest Asset Manangement LLC raised its position in Exelixis by 14.9% during the fourth quarter. NorthCrest Asset Manangement LLC now owns 13,536 shares of the biotechnology company's stock valued at $451,000 after acquiring an additional 1,758 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Exelixis during the fourth quarter valued at approximately $11,998,000. Forum Financial Management LP bought a new position in Exelixis during the fourth quarter valued at approximately $241,000. GF Fund Management CO. LTD. bought a new position in Exelixis during the fourth quarter valued at approximately $200,000. Finally, Neo Ivy Capital Management raised its position in Exelixis by 427.8% during the fourth quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company's stock valued at $1,794,000 after acquiring an additional 43,682 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total transaction of $58,812.00. Following the sale, the executive vice president now owns 693,181 shares in the company, valued at $27,034,059. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction on Friday, May 16th. The stock was sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the sale, the chief marketing officer now owns 465,393 shares in the company, valued at $21,161,419.71. This represents a 13.52% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 458,113 shares of company stock worth $21,024,817. Insiders own 2.85% of the company's stock.

Exelixis Trading Up 1.6%

Shares of Exelixis stock opened at $43.03 on Monday. The company's fifty day simple moving average is $39.03 and its 200-day simple moving average is $36.67. The company has a market cap of $11.73 billion, a price-to-earnings ratio of 24.31, a PEG ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a 1 year low of $21.36 and a 1 year high of $48.85.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Exelixis from $36.00 to $38.00 and gave the company a "hold" rating in a research report on Wednesday, May 14th. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Wells Fargo & Company reaffirmed a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Piper Sandler raised their price objective on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Finally, Bank of America raised their price objective on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.35.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.